Association between Mutation and Expression of TP53 as a Potential Prognostic Marker of Triple-Negative Breast Cancer

Cancer Research and Treatment : Official Journal of Korean Cancer Association
Ji-Yeon KimYeon Hee Park

Abstract

TP53, the most frequently mutated gene in breast cancer, is more frequently altered in HER2-enriched and basal-like breast cancer. However, no studies have clarified the role of TP53 status as a prognostic and predictive marker of triple-negative breast cancer (TNBC). We performed p53 immunohistochemistry (IHC), nCounter mRNA expression assay, and DNA sequencing to determine the relationship between TP53 alteration and clinical outcomes of TNBC patients. Seventy-seven of 174 TNBC patients were found to harbor a TP53 mutation. Patients with missense mutations showed high protein expression in contrast to patients with deletion mutations (positivity of IHC: wild type vs. missense vs. deletion mutation, 53.6% vs. 89.8% vs. 25.0%, respectively; p < 0.001). TP53 mRNA expression was influenced by mutation status (mRNA expression [median]: wild type vs. missense vs. deletion mutation, 207.36± 132.73 vs. 339.61±143.21 vs. 99.53±99.57, respectively; p < 0.001). According to survival analysis, neither class of mutation nor protein or mRNA expression status had any impact on patient prognosis. In subgroup analysis, low mRNA expression was associated with poor prognosis in patients with a TP53 missense mutation (5-year distant recurrence-f...Continue Reading

References

Feb 20, 1992·International Journal of Cancer. Journal International Du Cancer·A M ThompsonC M Steel
Nov 5, 1999·Advances in Cancer Research·P Hainaut, M Hollstein
Dec 1, 2000·Nature·B VogelsteinA J Levine
Jun 27, 2003·Proceedings of the National Academy of Sciences of the United States of America·Shunsuke KatoChikashi Ishioka
Sep 6, 2005·Proceedings of the National Academy of Sciences of the United States of America·Lance D MillerJonas Bergh
Feb 19, 2008·Nature Biotechnology·Gary K GeissKrassen Dimitrov
Jan 28, 2010·British Journal of Cancer·L BakerA M Thompson
Jun 3, 2011·The Journal of Clinical Investigation·Brian D LehmannJennifer A Pietenpol
Aug 5, 2011·Epigenetics : Official Journal of the DNA Methylation Society·Ricardo Saldaña-Meyer, Félix Recillas-Targa
Jun 23, 2012·Nature·Philip J StephensMichael R Stratton
Sep 25, 2012·Nature·UNKNOWN Cancer Genome Atlas Network
Mar 22, 2013·Database : the Journal of Biological Databases and Curation·Dongwan HongJeong-Sun Seo
Dec 30, 2014·International Journal of Cancer. Journal International Du Cancer·Yeon Hee ParkYoung-Hyuck Im

❮ Previous
Next ❯

Citations

Jul 30, 2017·Journal of Veterinary Diagnostic Investigation : Official Publication of the American Association of Veterinary Laboratory Diagnosticians, Inc·Táya F OliveiraAna Maria R Ferreira
Dec 12, 2018·The Kaohsiung Journal of Medical Sciences·Soo Youn BaeSeok Jin Nam
Apr 11, 2017·Oncology Reports·Jisela Dimas-GonzálezAlfredo Lagunas-Martínez
Mar 29, 2018·Breast Cancer Research and Treatment·Elisabetta MunzoneMarco Colleoni
Sep 29, 2020·Cancer Biomarkers : Section a of Disease Markers·Heyan ChenHuimin Zhang
Jan 8, 2021·Biology of Sex Differences·Lauren J MillsLindsay A Williams
Feb 18, 2020·Trends in Cancer·Ashkan ShahbandiJames G Jackson
May 3, 2021·Gynécologie, Obstétrique, Fertilité & Sénologie·M OsadaC Mathelin

❮ Previous
Next ❯

Methods Mentioned

BETA
biopsies
AmpliSeq
methylation sequencing

Software Mentioned

NanoString nSolver
SPSS Statistics
ANNOVAR
Ion Torrent Variant Caller
nCounter Digital Analyzer
Torrent Suite
Integrative Genomic Viewer

Related Concepts

Related Feeds

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.